IND Program CCTG

Congratulations @Philippe_Bedard on the ESMO-TAT Honorary Award 2025 @CDNCancerTrials

Academic consortia around the world linkedin.com/posts/jennyjia…

ENA 2024 is in Barcelona from 23-25 October! 🌟 Don’t miss out on the top-notch sessions and dynamic networking opportunities. Register today #ENASymp24 eortc.org/ena

OCE's Project SignifiCanT (Statistics in Cancer Trials) promotes collaboration and engagement among diverse stake holders to further the design and analysis of cancer clinical trials with the goal to advance cancer therapies. Learn more: fda.gov/about-fda/onco…

@peters_solange @ChristinaBYap @danieltanmd @GPentheroudakis @FAndreMD @curijoey @DrIgMelero @PaoloNuciforo @brainstrust @DMBranco

MDICT 2024 recommendations for neoadjuvant early clinical trials now published. Led by ESMO-TAT chairs @lillian_siu @ElenaGarralda @AnastasiosStat2 and MDICT’24 team supported by @myESMO sciencedirect.com/science/articl…

🎙️@PBarataMD of @UHhospitals and @lillian_siu of @pmcancercentre discuss recent state-of-the-art advancements in cancer vaccine development on the latest episode of the #ASCODailyNews Podcast: dailynews.ascopubs.org/do/podcast-era…

The @FDA's recent draft guidance on #DiversityActionPlans for clinical trials is an important step towards more inclusive and representative trials. Friends CEO Jeff Allen recently spoke to @RAPSorg about this guidance and its importance. raps.org/news-and-artic…

Register by September 4 to get the lowest available rates for the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (October 23-25, Barcelona, Spain), chaired by @VriesElisabeth, @TimGreten, and Timothy A. Yap. bit.ly/3VYkhbe #ENASymp24

Nerve cells were considered bystanders in the spread of #cancer. Dr. Sebastien Talbot has revealed that certain nerve cells are key to tumour survival. Learn more about his research supported by @azrielifdn & @BrainCanada: bit.ly/4f03SvK @queensuResearch @QueensuSCRI

Did you know smoking tobacco increases the risk of developing 18 types of cancers? Learn about ways to reduce the burden of cancer in the @AACR #CancerProgressReport. bit.ly/3zE6YoT

Explore the forefront of thoracic oncology at #WCLC24! With 6,000+ delegates from over 100 countries, it is a must-attend event for professionals in the field of lung and other thoracic cancers. Register by July 29 at wclc2024.iaslc.org/37mh

July is #SarcomaAwarenessMonth. Join us in raising awareness and supporting those affected by the battle against Sarcoma. #CCTG is inspired by the strength and resilience of all patients and families. We are committed to advancing research and helping improve lives.

Congratulations to former @cancersociety board member Dr Tony Fields, who served as president of the National Cancer Institute of Canada (CCS’s research arm before integration). A well-deserved recognition for an outstanding career and leadership!

🌟Attention students and trainees looking for a postdoc experience at @theNCI: The NCI Cancer Prevention Fellowship Program is accepting applications through Aug 1! Don’t miss this opportunity! cpfp.cancer.gov

#Breaking: Today, we provided an update on the Phase II/III trial evaluating our investigational anti-#TIGIT cancer immunotherapy in advanced non-squamous NSCLC. Learn more: gene.com/media/press-re…

⚠️ From press release on Skyscraper -06: Tira+Atezo +chemo INCREASED by 33% the risk of DEATH compared to Pembro +chemo 🤦🏻 Could ICI combos exert detrimental effect? More is NOT always better in IO and some ICI combos may have hetero-neutralizing impact on microenvironmental immune activation IMO we should abandon “chemo+Pembro+ “another ICI” trials in unselected populations and try to define molecularly selected subsets( co-mutations?) of pts who require combinatorial approaches #some #LCSM @OncoAlert @OncBrothers

Come and join us! We are recruiting a fully funded PhD student to our @MRCTMRPDTP with @ChristinaBYap at ICR. Please share widely. Closing date 15 August. For more information see mrctmrpdtp.com/current-opport…

Great news for Horizon Europe and Canada, this will lead to a wealth of opportunities for collaborative research! 🇪🇺

Retrospective look at impact of durvalumab on pneumonitis after chemoradiation for NSCLC @ClinicalLung. With durva, 57% G1 pneumonitis, 38% G2, 5% G3. Steroid course 17w with durva and 7w without. Pneumonitis relapse 23% with durvalumab, 7% without. clinical-lung-cancer.com/article/S1525-…